<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578548</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG2737-CL-203</org_study_id>
    <secondary_id>2019-003521-21</secondary_id>
    <nct_id>NCT04578548</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)</brief_title>
  <official_title>An Exploratory, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Orally Administered GLPG2737 for 52 Weeks, Followed by an Open-label Extension Period of 52 Weeks in Subjects With Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, randomized, double-blind, placebo-controlled, parallel group,&#xD;
      multicenter, proof of concept study (Phase 2a), evaluating orally administered GLPG2737 for a&#xD;
      double-blind (DB) treatment period of 52 weeks and 4 weeks of follow up as well as an&#xD;
      open-label extension (OLE) treatment period of 52 weeks and 4 weeks of follow-up, in subjects&#xD;
      with rapidly progressing ADPKD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline of Height-Adjusted Total Kidney Volume (htTKV)</measure>
    <time_frame>From baseline until 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Day 1 until 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 1 until 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With TEAEs According to Severity</measure>
    <time_frame>From Day 1 until 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With TEAEs Leading to Treatment Discontinuation</measure>
    <time_frame>From Day 1 until 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>From baseline until 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of GLPG2737, estimated based on population pharmacokinetics (PK) modelling</measure>
    <time_frame>predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 5-7, 8-9 hours postdose on Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of G1125498 (Major Active Metabolite of GLPG2737), estimated based on population PK modelling</measure>
    <time_frame>predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 5-7, 8-9 hours postdose on Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of GLPG2737, estimated based on population PK modelling</measure>
    <time_frame>predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 5-7, 8-9 hours postdose on Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of G1125498 (Major Active Metabolite of GLPG2737), estimated based on population PK modelling</measure>
    <time_frame>predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 5-7, 8-9 hours postdose on Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>DB Period: GLPG2737</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLPG2737 will be administered orally once daily with food for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DB Period: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered orally once daily with food for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLE Period: GLPG2737</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants completing the DB period (GLPG2737 and placebo arm) will enter an OLE period of 52 weeks where GLPG2737 will be administered orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules administered orally with food</description>
    <arm_group_label>DB Period: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2737</intervention_name>
    <description>Capsules administered orally with food</description>
    <arm_group_label>DB Period: GLPG2737</arm_group_label>
    <arm_group_label>OLE Period: GLPG2737</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria for the double-blind period of the study:&#xD;
&#xD;
          -  Documented diagnosis of typical ADPKD, using the Ravine criteria (Ravine, et al.,&#xD;
             1994).&#xD;
&#xD;
          -  Rapidly progressive disease, defined as presence of all of the following:&#xD;
&#xD;
               -  Total Kidney Volume (TKV) &gt;750 mL, as determined on imaging not older than 5&#xD;
                  years before screening. If historical imaging is not available or older than 5&#xD;
                  years, imaging can be performed during the screening period according to local&#xD;
                  clinical practice (that is, echography, magnetic resonance imaging [MRI])&#xD;
&#xD;
               -  Mayo ADPKD Classification Classes 1C to 1E.&#xD;
&#xD;
          -  eGFR at screening between 30 to 90 mL/min/1.73 m^2 for participants aged 18 to 40&#xD;
             years (inclusive), and between 30 to 60 mL/min/1.73 m^2 for participants aged 40 to 50&#xD;
             years.&#xD;
&#xD;
          -  Blood pressure ≤ 150/90 mmHg. In case a participant is treated for hypertension,&#xD;
             she/he should be on a stable treatment regimen of antihypertensive therapy for at&#xD;
             least 8 weeks prior to the screening visit, and during the screening period.&#xD;
&#xD;
        Key Inclusion Criteria for the OLE period of the study:&#xD;
&#xD;
          -  Male and female subjects who completed the 52-week double-blind treatment period on&#xD;
             investigational product (IP).&#xD;
&#xD;
          -  Subject, according to the investigator's judgment, may benefit from long-term&#xD;
             treatment with GLPG2737.&#xD;
&#xD;
        Key Exclusion Criteria for the double-blind period of the study:&#xD;
&#xD;
          -  Congenital absence of 1 kidney, or participant had a previous nephrectomy or has a&#xD;
             transplanted kidney or a transplantation is planned in the foreseeable future.&#xD;
&#xD;
          -  Administration of polycystic kidney disease-modifying agents (for example, tolvaptan,&#xD;
             somatostatin analogues) or interventions (such as cyst aspiration or cyst&#xD;
             fenestration) within 12 weeks prior to the screening visit and during the screening&#xD;
             period. In case tolvaptan is not being administered, this should be because of e.g.&#xD;
             non-availability, intolerance, or physician's clinical judgment.&#xD;
&#xD;
          -  Any condition or circumstances that, in the opinion of the investigator, may make a&#xD;
             participant unlikely or unable to complete the study or comply with study procedures&#xD;
             and requirements (for example, unable to undergo MRI due to participant's weight&#xD;
             exceeds the weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm&#xD;
             clips, severe claustrophobia, etc.).&#xD;
&#xD;
        Key exclusion criteria for the OLE period of the study:&#xD;
&#xD;
          -  Clinically significant abnormalities detected on 12-lead ECG of either rhythm or&#xD;
             conduction, QTcF &gt;450 ms, or long QT syndrome.&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Fieuw, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galapagos Medical Information</last_name>
    <phone>+32 15 342900</phone>
    <email>medicalinfo@glpg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires St. Luc (UCL)</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCSS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uni Campania L. Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri IRCCS</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Centrum Medyczne SCM Spółka z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DaVita Sp. z o.o. Stacja Dializ</name>
      <address>
        <city>Warsaw</city>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny UM w Lodzi</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nefrologia Clinica C.P.</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

